Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01627678

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

Immunotherapy of HIV-infected Patients An Open, Dose-escalating Assessment of Vacc-C5 With Either GM-CSF or Alhydrogel as Adjuvant in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Sponsor: Bionor Immuno AS

Conditions HIV-1 Infection

Interventions Vacc-C5/Alhydrogel Vacc-C5/GM-CSF

Updated 6 times since 2017 Last updated: Jan 13, 2014 Started: Sep 30, 2012 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on HIV-1 Infection, this trial is completed. The trial is conducted by Bionor Immuno AS and has accumulated 6 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bionor Immuno AS

Data source: Bionor Immuno AS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway